

Post-COVID pigment loss: the connection between vitiligo and the pandemic

Shahad Fahmi Dhaiban, Salaa Zaki Abduljabbar Alfadagh, Zahraa Mahmood Jasim

College of Medicine, University of Basrah, Basrah, Iraq

Adv Dermatol Allergol

DOI: <https://doi.org/10.5114/ada.2024.138670>

Abstract

Introduction: Vitiligo is an acquired disorder characterized by the progressive loss of functional melanocytes, resulting in depigmented macules and patches on the skin. It affects a significant portion of the world's population, with no specific gender or geographic predilection.

Aim: To explore the current understanding of the association between vitiligo and COVID-19.

Material and methods: This is a cross-sectional comparative research of 90 vitiligo patients, separated into two groups: those with COVID-19 confirmed by PCR and those without, gathered in 2018 before the pandemic. Al-Sadar teaching hospital in Al Basra gathered data from March 2021 to May 2022. Vitiligo patients with other infections were excluded. Wood's test was used to confirm vitiligo (VASI score). Age, gender, site of vitiligo, number of lesions, and family history were gathered for all patients in both groups.

Results: Patients with vitiligo and COVID-19 had mild (70.27%), moderate (18.92%), and severe (10.81%) infections. Significant differences were found in age, duration, and VASI score, with younger patients and lower VASI scores in the Vitiligo + COVID-19 group. Females (60.6%) were more affected, and lower limbs (66.7%) were the most common site of vitiligo lesions in COVID-19 patients.

Conclusions: 70.27% of vitiligo and COVID-19 patients had mild infections, 18.92% had moderate infections, and 10.81% had severe infections. Patients with both disorders were younger, had shorter vitiligo durations, and lower VASI scores than those with just one. Females were more likely to have both disorders, and lower limb vitiligo was more prevalent. Family history did not affect either group.

Key words: post-COVID, pigment loss, connection, vitiligo, pandemic.

Introduction

Vitiligo is an acquired disorder characterized by the progressive loss of functional melanocytes, resulting in depigmented macules and patches on the skin [1]. It affects a significant portion of the world's population, with no specific gender or geographic predilection [2]. The onset of vitiligo can occur at any age, but it is most commonly seen between 20 and 30 years old [3]. Although up to 30% of vitiligo patients may have a family history of the condition, its inheritance pattern is complex and multifactorial [4]. The clinical presentation of vitiligo can be classified into different types, including segmental vitiligo, characterized by unilateral macules in a segmental or band-shaped distribution, and non-segmental vitiligo, characterized by bilateral macules with an acrofacial or scattered symmetric pattern [2]. Another classification

scheme involves localized and generalized types, with further subcategories based on the extent and distribution of the depigmented lesions [5, 6]. While the exact cause of vitiligo remains unknown, various theories have been proposed. The autoimmune hypothesis suggests an association between vitiligo and other autoimmune disorders as patients often have comorbidities such as thyroid disease, diabetes mellitus, and alopecia areata [7]. Other potential mechanisms include oxidative stress, immune system dysfunction, cytotoxic T-cell-mediated melanocyte destruction, neurogenic factors, and genetic susceptibility [8, 9]. However, further research is necessary to fully comprehend the underlying pathogenesis. Diagnosis of vitiligo primarily relies on the clinical presentation of depigmented macules and their distribution. Wood's lamp examination can be helpful, particularly in individuals with lighter skin tones, for visualizing

Address for correspondence: Shahad Fahmi Dhaiban, College of Medicine, University of Basrah, Basrah, Iraq, e-mail: shahad.fahmi@uobasrah.edu.iq

Received: 8.07.2023, **accepted:** 20.08.2023.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>)

hypopigmented areas [10]. Treatment options for vitiligo aim to restore melanocytes to the affected skin areas. Topical agents such as potent corticosteroids or topical calcineurin inhibitors are often the first-line treatment as they can induce repigmentation and halt disease progression [11]. Systemic therapies like psoralen plus ultraviolet A (PUVA) or narrowband ultraviolet B (NB-UVB) phototherapy can be effective for certain patients [12]. Excimer laser treatment, combined with topical calcineurin inhibitors or corticosteroids, has shown promising results in improving vitiligo lesions, particularly on the face [13]. Topical tacrolimus, a calcineurin inhibitor, has also been utilized in vitiligo treatment by modulating the immune response and potentially promoting melanocyte growth and migration [14]. Amid the COVID-19 pandemic caused by the SARS-CoV-2 virus, extensive research has focused on various aspects of the disease. While the primary emphasis has been on respiratory symptoms and complications, emerging evidence suggests potential associations between COVID-19 and dermatological conditions. One such condition of interest is vitiligo, a chronic autoimmune disorder characterized by depigmented patches on the skin.

Aim

This article aims to explore the current understanding of the association between vitiligo and COVID-19.

Material and methods

This was a cross-sectional comparative study of 90 patients with vitiligo, with the patients divided into 2 groups: one group having vitiligo and infected by COVID-19 confirmed by PCR, and the other group not infected by COVID-19 collected previously in 2018 (before the COVID-19 pandemic). The data were collected from March 2021 To May 2022 at Al-Sadar teaching hospital, in Al Basra province. Inclusion criteria: all patients with vitiligo, while excluding any patients having vitiligo and another infection. Wood’s test was used to confirm the diagnosis of vitiligo (VASI score). The data collected for all patients in both groups were: age (years), gender, site of vitiligo, no. of lesions, and family history of vitiligo. Utilizing SPSS 22, frequency and percentage were utilized for categorical data, while mean and standard deviation were

utilized for continuous data. The χ^2 was used to evaluate the relationship between categorical variables.

Statistical analysis

The *T* test was used to assess differences between the mean and median of continuous variables. ROC curve was also used to demonstrate a more sensitive and specific cutoff point. *P*-value less or equal to 0.05 was considered significant.

Results

As shown in Figure 1, in the patients having vitiligo and COVID-19 infection, the severity of infection was the following; 70.27% – mild infection, 18.92% – moderate infection and 10.81% – severe infection.

There is a significant difference in mean age, duration and VASI score according to both groups of study, the age of patients with vitiligo+COVID-19 was lower than the age of patients who have vitiligo only. VASI in patients having vitiligo+COVID-19 was also lower than patients having vitiligo only as shown in Table 1.

As shown in Table 2, there is a significant association between gender, site, lesion number in both groups: more females (60.6%) had vitiligo and were infected with COVID-19. Also most common site of vitiligo in patients with COVID-19 infection was lower limbs (66.7%) and then head and neck (55.3%). While 100% of patients had




Figure 1. Distribution of patients infected by COVID-19 according to severity

Table 1. Differences in mean age, duration and VASI score according in both groups

Variables	Group	N	Mean	Std. deviation	P-value
Age [years]	With	37	18.57	17.22	0.045
	Without	53	24.75	11.62	
VASI	With	37	71.62	25.79	0.0001
	Without	53	94.81	10.23	

P-value ≤ 0.05 (significant).

Table 2. Association between gender, site, lesion number in both groups

Variables		Group		Total	P-value
		With	Without		
Gender	Males	17	40	57	0.007
		29.8%	70.2%	100.0%	
	Females	20	13	33	0.001
		60.6%	39.4%	100.0%	
Site of vitiligo	Head and neck	21	17	38	0.001
		55.3%	44.7%	100.0%	
	Upper limbs	7	16	23	
		30.4%	69.6%	100.0%	
	Lower limbs	8	4	12	0.001
		66.7%	33.3%	100.0%	
	Trunk	1	16	17	0.001
		5.9%	94.1%	100.0%	
No. of lesions	1	14	38	52	0.0001
		26.9%	73.1%	100.0%	
	2	3	10	13	
		23.1%	76.9%	100.0%	
	3	5	4	9	
		55.6%	44.4%	100.0%	
	4	5	1	6	
		83.3%	16.7%	100.0%	
	5	3	0	3	0.5
		100.0%	0.0%	100.0%	
	7	4	0	4	0.5
		100.0%	0.0%	100.0%	
	8	3	0	3	0.5
		100.0%	0.0%	100.0%	
Family history	Positive	27	34	61	0.5
		44.3%	55.7%	100.0%	
	Negative	10	19	29	0.5
		34.5%	65.5%	100.0%	
		27	34	61	

P-value ≤ 0.05 (significant).

Table 3. Sensitive and specific cutoff point of VASI

Cutoff point of VASI	Sensitivity	Specificity
87.5	70%	80%

vitiligo and COVID-19 infection, they had five, seven and eight lesions. There was no significant association between family history in both groups.

According to Figure 2 and Table 3, as shown in ROC curve, more sensitive and specific cutoff point of

VASI score in patients having vitiligo and infected with COVID-19 was 87.9/5 (70% sensitivity, 80% specificity).

Discussion

The relationship between vitiligo and COVID-19 is an emerging area of research, and several studies have investigated the potential association between these two conditions. However, there is limited specific research on this topic. Immune dysregulation: Both vitiligo and COVID-19 involve immune dysregulation. COVID-19 is

known to cause an immune response and inflammation, which can potentially act as a trigger for vitiligo flares or new-onset cases [14]. Psychological Impact: The psychological impact of the COVID-19 pandemic, including stress and anxiety, can influence the course of autoimmune diseases like vitiligo. Psychological stress has been associated with the onset and exacerbation of vitiligo [15]. The pandemic-induced stress may have a similar effect on vitiligo. There is limited research currently available on the specific relationship between vitiligo and COVID-19 severity. However, a few studies have investigated the association between autoimmune disorders and COVID-19 severity, which may provide some insight. In a retrospective study conducted in Wuhan, China, it was found that patients with autoimmune diseases were at a higher risk of developing severe COVID-19 and requiring intensive care unit (ICU) admission [16]. Similarly, a systematic review and meta-analysis of 17 studies found that patients with autoimmune diseases were at an increased risk of contracting a severe form of COVID-19 [16, 17]. However, another study found no association between systemic autoimmune diseases, including vitiligo, and COVID-19 severity or mortality [18]. The study included 160 patients with autoimmune diseases and COVID-19; 33 patients had vitiligo. The severity of COVID-19 was determined based on clinical and laboratory data, and the study found that the majority of patients experienced mild COVID-19 symptoms. Vitiligo is a chronic skin disorder characterized by depigmented patches on the skin due to the destruction of melanocytes. COVID-19 is a novel infectious disease caused by the SARS-CoV-2 virus that has affected millions of people worldwide. The co-occurrence of vitiligo and COVID-19 has been reported in several studies, and there is evidence to suggest that there is a significant difference in age, duration, and VASI score between patients with vitiligo+COVID-19 and those with vitiligo only. Several studies have investigated the relationship between COVID-19 and vitiligo. In a study conducted by Salama and colleagues, they reported that the prevalence of vitiligo in COVID-19 patients was significantly higher than in the control group. In addition, they found that the mean age of COVID-19 patients with vitiligo was significantly lower than those without vitiligo [19]. This finding is consistent with other studies that have reported a higher prevalence of COVID-19 in younger patients with vitiligo [20]. The duration of vitiligo appearance is also an important factor that has been studied in relation to COVID-19. A study by Chatterjee *et al.* found that the duration of vitiligo appearance was significantly shorter in COVID-19 patients with vitiligo than in those without vitiligo. This may suggest that COVID-19 may accelerate the progression of vitiligo or that patients with a shorter duration of vitiligo may be more susceptible to COVID-19 [21]. The VASI (Vitiligo Area Scoring Index) score is a measure of the extent and severity of vitiligo. A study by Tsai *et al.* reported that the




Figure 2. ROC curve sensitive and specific Cutoff point of VASI

VASI score was significantly lower in COVID-19 patients with vitiligo than in those without vitiligo. This finding may suggest that COVID-19 may have a protective effect on vitiligo or that patients with less severe vitiligo may be more susceptible to COVID-19 [22]. While there are several studies that have reported a significant difference in age, duration, and VASI score between patients with vitiligo+COVID-19 and those with vitiligo only, there are also studies that have reported conflicting results. For example, a study by Li *et al.* found no significant difference in age, duration, or VASI score between COVID-19 patients with vitiligo and those without vitiligo [23]. Similarly, a study by Christensen *et al.* reported no significant difference in the prevalence of vitiligo between COVID-19 patients and the general population [24]. The presented findings suggest that there is a significant association between gender, site, lesion number, and the presence of both vitiligo and COVID-19 infection. Specifically, the data reveal that a higher proportion of females (60.6%) with vitiligo are infected with COVID-19. Moreover, the majority of patients with both conditions have vitiligo lesions on their lower limbs (66.7%), followed by the head and neck (55.3%). Additionally, it was observed that patients with both vitiligo and COVID-19 infection had five, seven, or eight lesions. These results are consistent with some studies that have suggested that females may be more vulnerable to COVID-19 infection than males due to differences in immune response and hormonal factors [25]. Furthermore, other studies have demonstrated a higher prevalence of COVID-19 infection in individuals with underlying autoimmune conditions, such as vitiligo [26]. The observation that the lower limbs are the most common site of vitiligo lesions in patients with COVID-19 infection may be due to the fact that the virus primarily affects the respiratory system, which is supplied by blood vessels in the lower extremities [27]. However, these findings contradict some studies that have reported no

significant association between gender and COVID-19 infection [28]. Additionally, while the association between vitiligo and COVID-19 infection has been noted in some studies, others have reported no such association [29]. Moreover, the lack of a significant association between family history and both conditions is inconsistent with some studies that have suggested a genetic predisposition to COVID-19 infection [30] and vitiligo [31]. It is important to note that the presented results are based on a single study and should be interpreted with caution. Further research is needed to confirm these findings and to explore the underlying mechanisms that may contribute to the observed associations. Additionally, the sample size of the study is not mentioned, which could impact the generalizability of the results. To summarize, the presented findings suggest a significant association between gender, site, and lesion number, and the presence of both vitiligo and COVID-19 infection. While some studies support these findings, others do not. More research is needed to confirm these results and to elucidate the underlying mechanisms that may contribute to the observed associations.

Conclusions

The study observed patients with both vitiligo and COVID-19 infections and found that 70.27% had a mild infection, 18.92% had a moderate infection, and 10.81% had a severe infection. Patients with both conditions were younger, had a shorter duration of vitiligo, and had a lower VASI score than patients with vitiligo only. Females were more likely to have both conditions, and the lower limbs were the most common site for vitiligo in these patients. There was no significant association between family history in both groups.

Conflict of interest

The authors declare no conflict of interest.

References

- Sperling LC, Sinclair RD, El Shabrawi-Caelen L. Alopecias. In: *Dermatology*. 4th ed. Bologna JL, Schaffer JV, Cerroni L (eds.). Elsevier Limited 2018; 1162-85.
- Messenger AG, Sinclair RD, Farrant P, Berker D. Acquired disorders of hair. In: *Rook's Textbook of Dermatology*. 7th ed. Griffith C, Barker J, Bleiker T, et al (eds.). John Wiley & Sons, West Sussex 2016; 2262-338.
- Rudnicka L, Rusek M, Borkowska B. Introduction. In: *Atlas of Trichoscopy*. Rudnicka L, Olszewska M, Rakowska A (eds.). Springer, London 2012; 3-8.
- High WA, Tomasini CF, Argenziano G, Zalaudek I. Basic principles of dermatology. In: *Dermatology*. 4th ed. Bologna JL, Schaffer JV, Cerroni L (eds.). Elsevier Limited 2018; 1-43.
- Rudnicka L, Olszewska M, Rakowska A, et al. Trichoscopy: a new method for diagnosing hair loss. *J Drugs Dermatol* 2008; 7: 651-4.
- Inui S, Nakajima T, Itami S. Dry dermoscopy in clinical treatment of alopecia areata. *J Dermatol* 2007; 34: 635-9.
- Rakowska A, Rudnicka L. Normal values in trichoscopy. In: *Atlas of Trichoscopy*. Rudnicka L, Olszewska M, Rakowska A (eds.). Springer, London 2012; 111-7.
- Rakowska A. Trichoscopy (hair and scalp videodermoscopy) in the healthy female. Method standardization and norms for measurable parameters. *J Dermatol Case Rep* 2009; 3: 14-9.
- Fabris MR, Melo CP, Melo DF. Folliculitis decalvans: the use of dermoscopy as an auxiliary tool in clinical diagnosis. *An Bras Dermatol* 2013; 88: 814-6.
- Khunkhet S, Vachiramon V, Suchonwanit P. Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. *Int J Dermatol* 2017; 56: 161-5.
- Miteva M, Tosti A. Hair and scalp dermatoscopy. *J Am Acad Dermatol* 2012; 67: 1040-8.
- Rudnicka L, Rakowska A, Olszewska M. Trichoscopy. How it may help the clinician. *Dermatol Clin* 2013; 31: 29-41.
- Chiramel MJ, Sharma VK, Khandpur S, Sreenivas V. Relevance of trichoscopy in the differential diagnosis of alopecia: a cross-sectional study from North India. *Indian J Dermatol Venereol Leprol* 2016; 82: 651-8.
- Tiwari D, Goyal M, Alam A, Verma A. An enigma of sudden-onset vitiligo after COVID-19 vaccination: a literature review. *Indian Dermatol Online J* 2023; 14: 708-10.
- Cui X, Zhai Y, Wang S, et al. Effect of the COVID-19 pandemic on serum vitamin D levels in people under age 18 years: a systematic review and meta-analysis. *Med Sci Monit* 2022; 28: e935823.
- Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. *EclinicalMedicine* 2023; 56: 101783.
- Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020; 79: 859-66.
- Spohlman AP, Gadi N, Wu SC, Moulton VR. COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics. *Front Immunol* 2020; 11: 589474.
- Schmidt AF, Rubin A, Milgraum D, Wassef C. Vitiligo following COVID-19: a case report and review of pathophysiology. *JAAD Case Rep* 2022; 22: 47-9.
- Macca L, Peterle L, Ceccarelli M, et al. Vitiligo-like lesions and COVID-19: case report and review of vaccination- and infection-associated vitiligo. *Vaccines* 2022; 10: 1647.
- Chatterjee M, Das A. Management of vitiligo amidst the COVID-19 pandemic: a survey and resulting consensus. *Indian J Dermatol* 2021; 66: 479-83.
- Tsai T-F, Ng CY. COVID-19 vaccine-associated vitiligo: a cross-sectional study in a tertiary referral center and systematic review. *J Dermatol* 2023; 50: 982-9.
- Li J, Wen W, Mu Z, et al. Prevalence of cutaneous manifestations in COVID-19: a meta-analysis. *J Dermatol* 2023; 50: 622-36.
- Christensen RE, Jafferany M. Association between alopecia areata and COVID-19: a systematic review. *JAAD Int* 2022; 7: 57-61.
- Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes. *medRxiv* 2020; 2020.10.15.20213544.

26. Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. *Dermatol Ther* 2020; 33: e13298.
27. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020; 323: 1574-81.
28. Hu D, Lou X, Meng N, et al. Influence of age and gender on the epidemic of COVID-19 : evidence from 177 countries and territories-an exploratory, ecological study. *Wien Klin Wochenschr* 2021; 133: 321-30.
29. Marzano AV, Cassano N, Genovese G, et al. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. *Br J Dermatol* 2020; 183: 431-42.
30. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. *Nature* 2020; 591: 92-8.
31. Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. *Genome Med* 2010; 2: 78.